Novo Nordisk A/S
NOVO-B
Rang in aandelen
#107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aandeelprijs
$39.74
Marktkapitalisatie
$175.38B
Verandering (1 dag)
1.28%
Verandering (1 jaar)
-25.58%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)
Categorie
Healthcare
Omzet van Novo Nordisk A/S (NOVO-B)
Omzet in Jun 2026 TTM: $49.50B
Volgens de laatste financiële rapporten van Novo Nordisk A/S bedraagt de huidige omzet van het bedrijf (TTM) $49.50B. In 2024 behaalde het bedrijf een omzet van $40.52B een stijging ten opzichte van de omzet in het jaar 2023, die $34.39B bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Novo Nordisk A/S van 2001 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $49.50B | 1.95% |
| 2025 | $48.55B | 19.82% |
| 2024 | $40.52B | 17.82% |
| 2023 | $34.39B | 35.02% |
| 2022 | $25.47B | 18.29% |
| 2021 | $21.53B | 3.33% |
| 2020 | $20.84B | 13.79% |
| 2019 | $18.31B | 6.63% |
| 2018 | $17.17B | -4.59% |
| 2017 | $18.00B | 13.46% |
| 2016 | $15.86B | 0.88% |
| 2015 | $15.73B | 8.89% |
| 2014 | $14.44B | -6.28% |
| 2013 | $15.41B | 11.69% |
| 2012 | $13.80B | 19.42% |
| 2011 | $11.55B | 6.01% |
| 2010 | $10.90B | 10.52% |
| 2009 | $9.86B | 15.53% |
| 2008 | $8.54B | 3.65% |
| 2007 | $8.24B | 20.44% |
| 2006 | $6.84B | 28.15% |
| 2005 | $5.34B | -0.14% |
| 2004 | $5.34B | 18.51% |
| 2003 | $4.51B | 27.01% |
| 2002 | $3.55B | 25.45% |
| 2001 | $2.83B | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $79.67B | 60.96% |
US
|
|
| $99.34B | 100.70% |
US
|
|
| $64.39B | 30.08% |
US
|
|
| $66.40B | 34.15% |
US
|
|
| $73.95B | 49.40% |
CH
|
